Etarfion Drug Interactions

Vaccines: Patients receiving Etarfion may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Etarfion.
Patients with significant exposure to the varicella virus should temporarily discontinue Etarfion therapy and be considered for prophylactic treatment with varicella zoster immunoglobulin.
Immune-modulating biologic products: Concurrent Etanercept and Anakinra therapy, a 7% rate of serious infections was observed, and did not result in higher ACR response rates. The most common infections consisted of bacterial pneumonia, cellulitis, pulmonary fibrosis and pneumonia died due to respiratory failure, neutropenia (ANC <1x10⁹/L).
Concurrent administration of Abatacept and Etanercept resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit.
Cyclophosphamide: The use of Etarfion in patients receiving concurrent Cyclophosphamide therapy is not recommended.
Sulfasalazine: Patients in a clinical study who were on established therapy with Sulfasalazine, to which Etanercept was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Etanercept or Sulfasalazine alone. The clinical significance of this observation is unknown.